Showing results (31-40 of 49) with videos related to
Sort By:
Pageof 5
Pathology, Research and Practice|July 28, 2016
P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatmentJana K Striefler, Marianne Sinn, Uwe Pelzer, et al.Journal of Surgical Oncology|September 17, 2013
Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 studyMarianne Sinn, Jana K Striefler, Bruno V Sinn, et al.European Journal of Cancer (Oxford, England : 1990)|August 4, 2017
Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinomaPhilipp Lohneis, Marianne Sinn, Sven Bischoff, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2014
Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trialHelmut Oettle, Hanno Riess, Jens M Stieler, et al.Frontiers in Oncology|August 13, 2021
Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 StudyJana Käthe Striefler, Hanno Riess, Philipp Lohneis, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2015
Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 TrialUwe Pelzer, Bernhard Opitz, Gerd Deutschinoff, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2020
<i>TP53</i> Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 TrialMarianne Sinn, Bruno V Sinn, Denise Treue, et al.Pancreas|March 17, 2009
The role of epoxide hydrolase Y113H gene variant in pancreatic diseasesJohann Ockenga, Sebastian Strunck, Cora Post, et al.British Journal of Cancer|October 16, 2018
Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancerDavide Melisi, Rocio Garcia-Carbonero, Teresa Macarulla, et al.JAMA|January 18, 2007
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trialHelmut Oettle, Stefan Post, Peter Neuhaus, et al.Pageof 5